This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wan, M. Articles by Cao, X. Search for Related Content PubMed PubMed Citation Articles by Wan, M. Articles by Cao, X.

(American Journal of Pathology. 2005;166:1379-1392.)
© 2005 American Society for Investigative Pathology

SCF^ß-TrCP1 Controls Smad4 Protein Stability in Pancreatic Cancer Cells

Mei Wan^*, Jin Huang^*, Nirag C. Jhala^*, Ewan M. Tytler, Lei Yang^*, Selwyn M. Vickers, Yi Tang^*, Chongyuan Lu^*, Ning Wang^* and Xu Cao^*

From the Departments of Pathology^* and Surgery, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama

Smad4, also known as deleted in pancreatic carcinoma locus 4 (DPC4), is a critical co-factor in signal transduction pathways activated by transforming growth factor (TGF)-ß-related ligands that regulate cell growth and differentiation. Mutations in Smad4/DPC4 have been identified in 50% of pancreatic adenocarcinomas. Here we report that SCF^ß-TrCP1, a ubiquitin (E3) ligase, is a critical determinant for Smad4 protein degradation in pancreatic cancer cells. We found that F-box protein ß-TrCP1 in this E3 ligase interacted with Smad4 and that SCF^ß-TrCP1 inhibited TGF-ß biological activity in pancreatic cancer cells by decreasing Smad4 stability. Very low Smad4 protein levels in human pancreatic ductal adenocarcinoma cells were observed by immunohistochemistry. By analyzing pancreatic tumor-derived Smad4 mutants, we found that most point-mutated Smad4 proteins, except those within or very close to a mutation cluster region, exhibited higher interaction affinity with ß-TrCP1 and significantly elevated protein ubiquitination by SCF^ß-TrCP1. Furthermore, AsPC-1 and Caco-2, two cancer cell lines harboring Smad4 point mutations, exhibited rapid Smad4 protein degradation due to the effect of SCF^ß-TrCP1. Both Smad4 levels and TGF-ß signaling were elevated by retrovirus-delivered ß-TrCP1 siRNA in pancreatic cancer cells. Therefore, inhibition of Smad4-specific E3 ligase might be a target for therapeutic intervention in pancreatic cancer.

This article has been cited by other articles:

				E. Glasgow and L. Mishra Transforming growth factor-{beta} signaling and ubiquitinators in cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 59 - 72. [Abstract] [Full Text] [PDF]

				L.-H. Wang, S.-H. Kim, J. H. Lee, Y.-L. Choi, Y. C. Kim, T. S. Park, Y.-C. Hong, C.-F. Wu, and Y. K. Shin Inactivation of SMAD4 Tumor Suppressor Gene During Gastric Carcinoma Progression Clin. Cancer Res., January 1, 2007; 13(1): 102 - 110. [Abstract] [Full Text] [PDF]

				C. Chen, A. K. Seth, and A. E. Aplin Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer Mol. Cancer Res., October 1, 2006; 4(10): 695 - 707. [Abstract] [Full Text] [PDF]

				K. S. Richardson and W. Zundel The Emerging Role of the COP9 Signalosome in Cancer Mol. Cancer Res., December 1, 2005; 3(12): 645 - 653. [Abstract] [Full Text] [PDF]